Zoono’s Shelf-Life Tech Trials Reach 45; UK Roll-Out Expected Next Year
Zoono Group Limited reports strong progress in its shelf-life extension technology with 45 active trials worldwide and anticipates UK revenue by Q2 FY26 following successful supermarket partnerships.
- 45 ongoing shelf-life extension trials across four continents
- Successful UK in-store trials leading to Sharpak packaging agreement
- Expected national UK roll-out and revenue generation by Q2 FY26
- Orders received from Asian pharmaceutical and animal health sectors
- Financial stability supported by rights issue and reduced overheads
Global Expansion of Shelf-Life Extension Trials
Zoono Group Limited continues to make significant strides in its innovative shelf-life extension technology, now conducting 45 trials across the UK, Europe, Asia, Africa, and Australia. This marks an increase of 11 trials since the previous quarter, reflecting growing interest from a diverse range of customers including supermarket chains, food producers, packaging companies, and exporters. Initially focused on soft fruits, the trials have broadened to encompass a wider variety of fresh produce such as vegetables, meat, fish, poultry, bread, ready-meals, and even fresh flowers. Impressively, all trials to date have reported successful outcomes, underscoring the technology’s potential to transform food preservation.
UK Market Breakthrough and Strategic Partnerships
The UK remains the most advanced market for Zoono’s shelf-life extension products. Two major supermarket chains conducted in-store trials in March 2025, which led to a pivotal agreement with Sharpak, a leading food packaging supplier to supermarkets in the UK and France. This partnership is a critical step towards a full national roll-out anticipated by the second quarter of fiscal year 2026. Further trials with another large UK supermarket chain are planned, reinforcing the company’s confidence in imminent revenue generation from this sector.
Progress in Asian and Animal Health Markets
Beyond the shelf-life extension project, Zoono has secured orders from a major Japanese pharmaceutical company for products intended for the textile industry, signaling diversification of its commercial applications. Additionally, the company expects repeat orders in the Australian animal health market in the coming quarter, highlighting ongoing demand across multiple sectors and geographies.
Financial Position and Funding Initiatives
Despite a net cash outflow from operating activities during the quarter, Zoono’s financial footing is bolstered by a recent non-renounceable rights issue, which raised additional capital with full participation from the board. The company has also implemented significant overhead reductions and maintains access to financing facilities, including a loan from MEG Trust. These measures collectively position Zoono to meet its near-term operational objectives and support the anticipated ramp-up in sales.
Outlook and Strategic Focus
Looking ahead, Zoono is focused on converting its extensive trial activity into commercial revenue streams, particularly through the UK supermarket channel. The company’s strategy to leverage existing inventory to reduce costs and its ongoing engagement with potential customers worldwide suggest a deliberate and measured approach to scaling its business. While challenges remain, especially in securing sustained cash flow, the groundwork laid this quarter provides a promising foundation for growth.
Bottom Line?
Zoono’s expanding global trials and strategic UK partnerships set the stage for revenue growth, but cash flow management remains critical.
Questions in the middle?
- How quickly will Zoono convert successful trials into sustained commercial contracts?
- What are the detailed terms and expected financial impact of the Sharpak agreement?
- Will the company secure additional funding or partnerships to extend its cash runway beyond Q2 FY26?
